Review
Otorhinolaryngology
Yongyuan Xue, Guoping Li, Tao Xie, Hongyang Xu, Tianrui Xu, Zhengfei Li, Lixiu Zhu, Xin Li, Zhiyao Li, Wei Xiong
Summary: This study systematically reviewed the significance of concurrent chemoradiotherapy for stage II nasopharyngeal cancer. The results showed that in the era of intensity-modulated radiotherapy, concurrent chemoradiotherapy and radiotherapy alone have the same survival benefits and concurrent chemoradiotherapy increases acute hematological toxicity. Subgroup analysis showed that for people with N1 nasopharyngeal cancer at risk of distant metastases, concurrent chemoradiotherapy and radiotherapy alone also had equal survival benefits.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
(2023)
Article
Oncology
Shan-Shan Yang, Ya-Jun Pang, Zhi-Qiang Wang, Bao-Yu Zhang, Zhi-Qiao Liu, En-Ni Chen, Pu-Yun Ouyang, Fang-Yun Xie
Summary: A risk score model was developed and validated to accurately select high-risk stage II NPC patients for CCRT treatment in the era of IMRT, guiding individualized treatment.
Article
Oncology
YuLin Lai, ChengTao Wang, XingLi Yang, ShaSha He, Yan Wang, Yong Chen
Summary: The efficacy of induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) in stage II nasopharyngeal carcinoma (NPC) treated with intensity-modulated radiotherapy (IMRT) was explored. The results showed that adding IC to CCRT or IMRT alone decreased progression-free survival (PFS) and distant metastasis-free survival (DMFS), indicating that IC should not be recommended in stage II NPC patients. There were no significant differences observed in overall survival (OS) and locoregional relapse-free survival (LRRFS) in stage II disease. In addition, high neutrophil-to-lymphocyte ratio was negatively associated with OS, PFS, and DMFS.
Article
Multidisciplinary Sciences
Shi-Ting Huang, Dan-Ke Su
Summary: This study assessed the survival outcomes among subgroups of stage II nasopharyngeal carcinoma patients and found that the subgroups were not independent prognostic factors for overall survival or cancer-specific survival.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Kaixuan Yang, Qian Zhang, Mengxi Zhang, Wenji Xie, Mei Li, Lei Zeng, Qiang Wang, Jianling Zhao, Yiping Li, Guangjun Li
Summary: A quantitative risk assessment model was developed to help stage II-IVa nasopharyngeal carcinoma patients determine the need for concurrent chemotherapy. Patients with low risk may benefit from concurrent chemotherapy, while those at high risk may require additional adjuvant chemotherapy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Zhouying Peng, Yumin Wang, Yaxuan Wang, Ruohao Fan, Kelei Gao, Hua Zhang, Weihong Jiang
Summary: This meta-analysis compared the efficacy of IMRT and ES for high T-stage recurrent NPC. Results suggest that ES may improve survival in recurrent NPC with rT3-4, with potentially fewer complications. More studies are needed to confirm these findings.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Won Il Jang, Sunmi Jo, Ji Eun Moon, Sun Hyun Bae, Hee Chul Park
Summary: This study is the first systematic review and meta-analysis on the advantages of IMRT for hepatocellular carcinoma. Despite most patients being in advanced stages and using combined treatment, IMRT for HCC showed similar survival rates to existing radiotherapy modalities and relatively low toxicity.
Article
Oncology
Fen Xue, Xiaoshuang Niu, Chaosu Hu, Xiayun He
Summary: This study aimed to determine the long-term risk of second primary lung adenocarcinoma (SPLAC) in nasopharyngeal cancer (NPC) patients after intensity-modulated radiotherapy (IMRT). The results showed that the incidence of SPLAC in NPC patients after IMRT was similar to that of the normal population, and most cases were detected in early stages during follow-up, with good surgical efficacy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Guanzhu Shen, Yinglin Peng, Jian Li, Haijun Wu, Guangshun Zhang, Chong Zhao, Xiaowu Deng
Summary: This study evaluated the incidence of hypothyroidism in patients with nasopharyngeal carcinoma after IMRT, finding that 34.8% of patients developed hypothyroidism 12 months after radiotherapy. The average thyroid dose and thyroid volume were identified as key factors affecting hypothyroidism, with an NTCP model constructed based on these factors showing good fit.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Yi-Jun Hua, Yan-Feng Ou-Yang, Xiong Zou, Le Xia, Dong-Hua Luo, Ming-Yuan Chen
Summary: Radiotherapy is crucial for nasopharyngeal carcinoma patients, with a typical treatment duration of six to six and a half weeks. Prolonged radiotherapy duration is associated with higher risk of distant metastasis and death, highlighting the importance of avoiding prolonged treatment to improve outcomes.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Xing-Li Yang, Guan-Qun Zhou, Li Lin, Lu-Lu Zhang, Fo-Ping Chen, Jia-Wei Lv, Jia Kou, Dan-Wan Wen, Jun Ma, Ying Sun, Yan-Ping Mao
Summary: The study investigated the impact of interruptions during radiation therapy on the survival of nasopharyngeal carcinoma patients. It found that interruptions longer than specific thresholds significantly affected patient survival. Efforts should be made to minimize these interruptions and provide timely treatment.
Article
Medicine, General & Internal
Xiaoshuang Niu, Fen Xue, Peiyao Liu, Chaosu Hu, Xiayun He
Summary: Satisfactory locoregional control was achieved in nasopharyngeal carcinoma patients with T1-2N0-3M0 stage treated with intensity-modulated radiotherapy (IMRT). Distant metastasis was the main cause of treatment failure, and N2-3 disease was the main adverse prognostic factor. Additionally, the occurrence of second primary tumor negatively impacted overall survival in NPC patients.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
(2022)
Article
Oncology
Pengjie Ji, Qiongjiao Lu, Xiaoqiang Chen, Yuebing Chen, Xiane Peng, Zhiwei Chen, Cheng Lin, Shaojun Lin, Jingfeng Zong
Summary: This retrospective study aimed to re-evaluate the effect of concurrent chemotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC) in the era of intensity-modulated radiotherapy (IMRT). The results showed that pretreatment EBV DNA level can be used to individualize concurrent chemotherapy for patients with locally advanced NPC.
CANCER RESEARCH AND TREATMENT
(2023)
Article
Pharmacology & Pharmacy
Pei-Jing Li, Yu-Lin Lai, Fang He, Yuan-Yuan Chen, Zhuo-Sheng Gu, Wei Luo, Qun Zhang
Summary: This study compared the treatment outcomes of concurrent chemoradiotherapy (CCRT) versus radiotherapy (RT) alone in stage II nasopharyngeal carcinoma (NPC) patients. The findings showed no significant difference in survival rates and various survival indicators between the CCRT and RT groups. In the era of 2DRT, concurrent chemotherapy significantly improved some survival rates, but it had no significant effect in the era of intensity-modulated radiotherapy (IMRT).
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Lin Chen, Jing Li, Kunpeng Li, Jiang Hu, Qingjie Li, Chenglong Huang, Gaoyuan Wang, Na Liu, Linglong Tang
Summary: This study analyzed the probability of hearing impairment after radiotherapy for nasopharyngeal carcinoma and developed a predictive model, providing dose limitation suggestions to improve patients' quality of life.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Y. -P. Chen, Y. -Q. Wang, J. -W. Lv, Y. -Q. Li, M. L. K. Chua, Q. -T. Le, N. Lee, A. Dimitrios Colevas, T. Seiwert, D. N. Hayes, N. Riaz, J. B. Vermorken, B. O'Sullivan, Q. -M. He, X. -J. Yang, L. -L. Tang, Y. -P. Mao, Y. Sun, N. Liu, J. Ma
ANNALS OF ONCOLOGY
(2019)
Article
Endocrinology & Metabolism
Jia-Wei Lv, Zi-Qi Zheng, Zi-Xian Wang, Guan-Qun Zhou, Lei Chen, Yan-Ping Mao, Ai-Hua Lin, Russel J. Reiter, Jun Ma, Yu-Pei Chen, Ying Sun
JOURNAL OF PINEAL RESEARCH
(2019)
Article
Oncology
Ya-Qin Wang, Jia-Wei Lv, Ling-Long Tang, Xiao-Jing Du, Lei Chen, Wen-Fei Li, Xu Liu, Ying Guo, Ai-Hua Lin, Yan-Ping Mao, Ying Sun, Yu-Pei Chen, Jun Ma
Article
Oncology
Liang Peng, Cheng Xu, Yu-Pei Chen, Rui Guo, Yan-Ping Mao, Ying Sun, Jun Ma, Ling-Long Tang
Review
Radiology, Nuclear Medicine & Medical Imaging
Liang Peng, Jin-Qi Liu, Yu-Pei Chen, Jun Ma
BRITISH JOURNAL OF RADIOLOGY
(2019)
Meeting Abstract
Oncology
Jia-Wei Lv, Ying Sun, Yu-Pei Chen, Guan-Qun Zhou, Kuan Rui Lloyd Tan, Jun Ma, Melvin L. K. Chua
JOURNAL OF CLINICAL ONCOLOGY
(2019)
Letter
Oncology
Yu-Tong Chen, Jia-Yi Shen, Dong-Ping Chen, Chen-Fei Wu, Rui Guo, Pan-Pan Zhang, Jia-Wei Lv, Wen-Fei Li, Zi-Xian Wang, Yu-Pei Chen
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2020)
Article
Cell Biology
Yu-Pei Chen, Jian-Hua Yin, Wen-Fei Li, Han-Jie Li, Dong-Ping Chen, Cui-Juan Zhang, Jia-Wei Lv, Ya-Qin Wang, Xiao-Min Li, Jun-Yan Li, Pan-Pan Zhang, Ying-Qin Li, Qing-Mei He, Xiao-Jing Yang, Yuan Lei, Ling-Long Tang, Guan-Qun Zhou, Yan-Ping Mao, Chen Wei, Ke-Xu Xiong, Hong-Bo Zhang, Shi-Da Zhu, Yong Hou, Ying Sun, Michael Dean, Ido Amit, Kui Wu, Dong-Ming Kuang, Gui-Bo Li, Na Liu, Jun Ma
Article
Oncology
Ya-Qin Wang, Lei Chen, Yan-Ping Mao, Ying-Qing Li, Wei Jiang, Shuo-Yu Xu, Yu Zhang, Yu-Pei Chen, Xiao-Min Li, Qing-Mei He, Shi-Wei He, Xiao-Jing Yang, Yuan Lei, Yin Zhao, Jing-Ping Yun, Na Liu, Yingqin Li, Jun Ma
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2020)
Article
Oncology
Yin Zhao, Xiao-Hong Hong, Kang Li, Ying-Qing Li, Ying-Qin Li, Shi-Wei He, Pan-Pan Zhang, Jun-Yan Li, Qian Li, Ye-Lin Liang, Yang Chen, Jun Ma, Na Liu, Yu-Pei Chen
CANCER COMMUNICATIONS
(2020)
Article
Oncology
Yu-Pei Chen, Nofisat Ismaila, Melvin L. K. Chua, A. Dimitrios Colevas, Robert Haddad, Shao Hui Huang, Joseph T. S. Wee, Alexander C. Whitley, Jun-Lin Yi, Sue S. Yom, Anthony T. C. Chan, Chao-Su Hu, Jin-Yi Lang, Quynh-Thu Le, Anne W. M. Lee, Nancy Lee, Jin-Ching Lin, Brigette Ma, Thomas J. Morgan, Jatin Shah, Ying Sun, Jun Ma
Summary: This joint guideline provides evidence-based recommendations for definitive-intent chemoradiotherapy for patients with stage II-IVA nasopharyngeal carcinoma, addressing various aspects of care such as radiotherapy, chemotherapy sequence, and concurrent, induction, and adjuvant chemotherapy options.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Yu-Pei Chen, Jia-Wei Lv, Yan-Ping Mao, Xiao-Min Li, Jun-Yan Li, Ya-Qin Wang, Cheng Xu, Ying-Qin Li, Qing-Mei He, Xiao-Jing Yang, Yuan Lei, Jia-Yi Shen, Ling-Long Tang, Lei Chen, Guan-Qun Zhou, Wen-Fei Li, Xiao-Jing Du, Rui Guo, Xu Liu, Yuan Zhang, Jing Zeng, Jing-Ping Yun, Ying Sun, Na Liu, Jun Ma
Summary: This study identified immune-enriched and non-immune subtypes in nasopharyngeal carcinoma patients, as well as tumor immune evasion and active immune subtypes within the immune-enriched group. The active immune subtype predicted favorable survival and improved immune checkpoint inhibitor response compared to the immune evasion subtype.
Article
Medicine, General & Internal
Yu-Pei Chen, Xu Liu, Qin Zhou, Kun-Yu Yang, Feng Jin, Xiao-Dong Zhu, Mei Shi, Guo-Qing Hu, Wei-Han Hu, Yan Sun, Hong-Fen Wu, Hui Wu, Qin Lin, Hui Wang, Ye Tian, Ning Zhang, Xi-Cheng Wang, Liang-Fang Shen, Zheng-Zheng Liu, Jing Huang, Xiu-Ling Luo, Ling Li, Jian Zang, Qi Mei, Bao-Min Zheng, Dan Yue, Jing Xu, San-Gang Wu, Yan-Xia Shi, Yan-Ping Mao, Lei Chen, Wen-Fei Li, Guan-Qun Zhou, Rui Sun, Rui Guo, Yuan Zhang, Cheng Xu, Jia-Wei Lv, Ying Guo, Hui-Xia Feng, Ling-Long Tang, Fang-Yun Xie, Ying Sun, Jun Ma
Summary: This study found that adding oral metronomic capecitabine as adjuvant chemotherapy significantly improved failure-free survival in patients with high-risk locoregionally advanced nasopharyngeal carcinoma, with a good safety profile. These results support the potential role of metronomic chemotherapy as an adjuvant therapy in the treatment of nasopharyngeal carcinoma.
Meeting Abstract
Oncology
Ya-Qin Wang, Jia-Wei Lv, Ling-Long Tang, Xiao-Jing Du, Lei Chem, Wen-Fei Li, Xu Liu, Ying Guo, Ai-Hua Lin, Yan-Ping Mao, Ying Sun, Yu-Pei Chen, Jun Ma
Article
Oncology
Jun-Yan Li, Cheng-Long Huang, Wei-Jie Luo, Yuan Zhang, Ling-Long Tang, Hao Peng, Ying Sun, Yu-Pei Chen, Jun Ma
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2019)